DK1076704T3 - IL-2-selektive agonister og antagonister - Google Patents

IL-2-selektive agonister og antagonister

Info

Publication number
DK1076704T3
DK1076704T3 DK99924232T DK99924232T DK1076704T3 DK 1076704 T3 DK1076704 T3 DK 1076704T3 DK 99924232 T DK99924232 T DK 99924232T DK 99924232 T DK99924232 T DK 99924232T DK 1076704 T3 DK1076704 T3 DK 1076704T3
Authority
DK
Denmark
Prior art keywords
antagonists
selective agonists
agonists
selective
Prior art date
Application number
DK99924232T
Other languages
Danish (da)
English (en)
Inventor
Armen B Shanafelt
Jeffrey M Greve
Kenneth J Lembach
Gary Jesmok
Gayle D Wetzel
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Application granted granted Critical
Publication of DK1076704T3 publication Critical patent/DK1076704T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK99924232T 1998-05-15 1999-05-13 IL-2-selektive agonister og antagonister DK1076704T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8008098A 1998-05-15 1998-05-15
PCT/US1999/010643 WO1999060128A1 (en) 1998-05-15 1999-05-13 Il-2 selective agonists and antagonists

Publications (1)

Publication Number Publication Date
DK1076704T3 true DK1076704T3 (da) 2007-03-12

Family

ID=22155135

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99924232T DK1076704T3 (da) 1998-05-15 1999-05-13 IL-2-selektive agonister og antagonister

Country Status (39)

Country Link
EP (1) EP1076704B1 (zh)
JP (1) JP4276783B2 (zh)
KR (1) KR100607609B1 (zh)
CN (2) CN101319247B (zh)
AR (1) AR020322A1 (zh)
AT (1) ATE351907T1 (zh)
AU (1) AU759697B2 (zh)
BG (1) BG65139B1 (zh)
BR (1) BRPI9910504B1 (zh)
CA (1) CA2327349C (zh)
CO (1) CO5070701A1 (zh)
CU (2) CU23273B7 (zh)
CY (1) CY1107533T1 (zh)
CZ (1) CZ302071B6 (zh)
DE (1) DE69934881T2 (zh)
DK (1) DK1076704T3 (zh)
DZ (1) DZ2788A1 (zh)
ES (1) ES2281175T3 (zh)
HK (1) HK1039963B (zh)
HN (1) HN1999000075A (zh)
HU (1) HU226142B1 (zh)
IL (2) IL139136A0 (zh)
MY (1) MY130274A (zh)
NO (1) NO329235B1 (zh)
NZ (1) NZ508098A (zh)
PA (1) PA8472601A1 (zh)
PE (1) PE20000475A1 (zh)
PL (1) PL201675B1 (zh)
PT (1) PT1076704E (zh)
RO (1) RO122150B1 (zh)
RU (1) RU2235729C2 (zh)
SI (1) SI20643B (zh)
SK (1) SK288100B6 (zh)
SV (1) SV1999000061A (zh)
TN (1) TNSN99090A1 (zh)
TR (1) TR200003354T2 (zh)
TW (1) TWI223663B (zh)
UA (1) UA73719C2 (zh)
WO (1) WO1999060128A1 (zh)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058456A2 (en) 1999-03-30 2000-10-05 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
EP1935431A3 (en) 2000-05-15 2008-08-13 Health Research, Inc. Cancer treatments by using a combination of an antibody against her2 and interleukin-2
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
US7723102B2 (en) * 2000-09-28 2010-05-25 Bayer Corporation Enhanced transfection system
MY139948A (en) * 2000-09-28 2009-11-30 Bayer Corp Enhanced transfection system
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
BR0214650A (pt) * 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
EP1682178B8 (en) 2003-11-04 2010-09-01 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for cancers expressing the cd40 antigen
WO2005085282A1 (en) * 2004-02-27 2005-09-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity
WO2005091956A2 (en) * 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
CN101244261B (zh) * 2008-03-10 2010-09-15 山东大学 一种含未复性重组蛋白的生物制剂及其制备方法与应用
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
JP5766124B2 (ja) 2009-01-21 2015-08-19 アムジェン インコーポレイテッド 炎症性疾患および自己免疫疾患の処置の組成物および方法
CN102101885B (zh) * 2010-09-01 2013-06-05 南京发士达生物科技有限公司 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
KR102472497B1 (ko) 2010-11-12 2022-11-29 넥타르 테라퓨틱스 Il-2 부분 및 중합체의 접합체
EP3211001B1 (en) * 2010-12-22 2020-10-07 The Board of Trustees of the Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
WO2012119093A1 (en) * 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
US10781242B2 (en) 2013-09-24 2020-09-22 Medicenna Therapeutics Inc. Interleukin-2 fusion proteins and uses thereof
EP3102595B1 (en) 2014-02-06 2018-11-07 F.Hoffmann-La Roche Ag Interleukin-2 fusion proteins and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3134102B1 (en) 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
HUE051414T2 (hu) 2014-08-11 2021-03-01 Delinia Inc Módosított IL-2 változatok, amelyek szelektíven aktiválnak regulátor T sejteket, autoimmun betegségek kezelésére
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US20200316118A1 (en) * 2016-05-19 2020-10-08 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
RU2756236C2 (ru) 2016-06-20 2021-09-28 Кимаб Лимитед PD-L1 специфические антитела
JP7206190B2 (ja) * 2016-06-22 2023-01-17 ダヴィド・クラッツマン 遺伝的に修飾されたtリンパ球
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US11077172B2 (en) 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
CA3044416A1 (en) * 2016-12-13 2018-06-21 Delinia, Inc. Multivalent regulatory t cell modulators
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
SG11201909949XA (en) 2017-05-24 2019-11-28 Pandion Therapeutics Inc Targeted immunotolerance
WO2018215938A1 (en) * 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
US11542312B2 (en) 2017-06-19 2023-01-03 Medicenna Therapeutics, Inc. IL-2 superagonists in combination with anti-PD-1 antibodies
MX2020001336A (es) * 2017-08-03 2020-08-20 Synthorx Inc Conjugados de citoquina para el tratamiento de enfermedades autoinmunes.
AU2018372167B2 (en) * 2017-11-21 2023-12-07 The Board Of Trustees Of The Leland Stanford Junior University Partial agonists of interleukin-2
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
KR20200100098A (ko) 2017-12-19 2020-08-25 젠코어 인코포레이티드 조작된 il-2 fc 융합 단백질
US11534479B2 (en) 2018-02-16 2022-12-27 Iltoo Pharma Use of interleukin 2 for treating Sjögren's syndrome
IL277572B2 (en) 2018-03-28 2024-05-01 Ascendis Pharma Oncology Div A/S IL-2 conjugates
AU2019244091B2 (en) 2018-03-28 2023-12-07 Bristol-Myers Squibb Company Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
CN112771072A (zh) * 2018-07-24 2021-05-07 生物技术Rna制药有限公司 Il2激动剂
EP3836954A1 (en) 2018-08-13 2021-06-23 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
BR112020015030A2 (pt) * 2018-09-17 2021-03-16 Gi Innovation, Inc. Proteína de fusão compreendendo a proteína il-2 e a proteína cd80 e uso da mesma
TW202034945A (zh) 2018-12-21 2020-10-01 大陸商江蘇恆瑞醫藥股份有限公司 一種人白細胞介素2變體或其衍生物
TW202110885A (zh) 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向MAdCAM之免疫耐受性
TW202115105A (zh) * 2019-06-24 2021-04-16 德商拜恩迪克Rna製藥有限公司 Il2激動劑
AU2020328038A1 (en) * 2019-08-13 2022-03-31 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
WO2021116444A1 (en) 2019-12-12 2021-06-17 Iltoo Pharma Interleukin 2 chimeric constructs
KR20220114595A (ko) 2019-12-17 2022-08-17 암젠 인크 치료에서의 사용을 위한 이중 인터류킨-2/tnf 수용체 효현제
AU2021206449A1 (en) 2020-01-10 2022-07-21 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
KR102653906B1 (ko) 2020-01-14 2024-04-03 신테카인, 인크. 편향된 il2 뮤테인 방법 및 조성물
EP4107187A1 (en) 2020-02-21 2022-12-28 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
CA3175717A1 (en) 2020-03-19 2021-09-23 Innovent Biologics (Suzhou) Co., Ltd. Interleukin-2 mutant and use thereof
EP4130027A1 (en) * 2020-03-31 2023-02-08 Hanmi Pharm. Co., Ltd. Novel immunoactive interleukin 2 analog
EP4161956A1 (en) 2020-06-03 2023-04-12 Ascendis Pharma Oncology Division A/S Il-2 sequences and uses thereof
WO2022094275A1 (en) 2020-10-29 2022-05-05 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
CN114507643A (zh) * 2020-10-29 2022-05-17 未来智人再生医学研究院(广州)有限公司 一种表达il-2的多能干细胞衍生物及应用
CN113308477A (zh) * 2021-04-08 2021-08-27 华南农业大学 一种鸭il-2基因真核表达重组质粒及其制备方法
CA3233075A1 (en) 2021-09-22 2023-03-30 Fortvita Biologics (Singapore) Pte. Ltd. Interleukin-2 mutant and fusion protein thereof
AU2022360645A1 (en) 2021-10-06 2024-05-02 Assistance Publique - Hôpitaux De Paris Interleukin 2 chimeric constructs with targeting specificity to inflamed tissues
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
WO2023245097A2 (en) * 2022-06-16 2023-12-21 Cephalon Llc Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder
FR3140287A1 (fr) 2022-10-03 2024-04-05 Arkema France Procede de granulation de composes azoiques et granules obtenus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13

Also Published As

Publication number Publication date
CA2327349A1 (en) 1999-11-25
HUP0101948A3 (en) 2003-08-28
HN1999000075A (es) 1999-09-29
CU23272A1 (es) 2008-04-09
AU759697B2 (en) 2003-04-17
PL344407A1 (en) 2001-11-05
CO5070701A1 (es) 2001-08-28
NO20005762L (no) 2001-01-11
TWI223663B (en) 2004-11-11
RO122150B1 (ro) 2009-01-30
CN1309705A (zh) 2001-08-22
EP1076704B1 (en) 2007-01-17
PL201675B1 (pl) 2009-04-30
KR20010043602A (ko) 2001-05-25
HK1039963A1 (en) 2002-05-17
ES2281175T3 (es) 2007-09-16
PA8472601A1 (es) 2000-09-29
CN101319247B (zh) 2012-12-12
AU4078499A (en) 1999-12-06
NO20005762D0 (no) 2000-11-14
DZ2788A1 (fr) 2003-12-01
TR200003354T2 (tr) 2001-03-21
BG65139B1 (bg) 2007-03-30
SV1999000061A (es) 2000-03-14
EP1076704A1 (en) 2001-02-21
SI20643B (sl) 2008-02-29
HUP0101948A2 (hu) 2001-09-28
WO1999060128A1 (en) 1999-11-25
SI20643A (sl) 2002-02-28
BR9910504A (pt) 2001-01-09
BG104929A (en) 2001-09-28
NO329235B1 (no) 2010-09-20
CU23273B7 (es) 2008-04-09
DE69934881T2 (de) 2007-11-08
CA2327349C (en) 2010-10-26
BRPI9910504B1 (pt) 2016-08-09
IL139136A0 (en) 2001-11-25
KR100607609B1 (ko) 2006-08-02
AR020322A1 (es) 2002-05-08
NZ508098A (en) 2003-09-26
UA73719C2 (en) 2005-09-15
HK1039963B (zh) 2008-09-05
MY130274A (en) 2007-06-29
ATE351907T1 (de) 2007-02-15
JP2002515247A (ja) 2002-05-28
DE69934881D1 (de) 2007-03-08
SK288100B6 (sk) 2013-07-02
TNSN99090A1 (fr) 2005-11-10
CY1107533T1 (el) 2013-03-13
HU226142B1 (en) 2008-05-28
PT1076704E (pt) 2007-02-28
CN101319247A (zh) 2008-12-10
SK17242000A3 (sk) 2001-07-10
RU2235729C2 (ru) 2004-09-10
IL139136A (en) 2009-05-04
JP4276783B2 (ja) 2009-06-10
CZ20004213A3 (en) 2001-05-16
PE20000475A1 (es) 2000-07-07
CZ302071B6 (cs) 2010-09-29
CN100366742C (zh) 2008-02-06

Similar Documents

Publication Publication Date Title
DK1076704T3 (da) IL-2-selektive agonister og antagonister
NO20004778D0 (no) Amidderivater og nociceptin antagonister
NO20032753L (no) Forbindelse og anvendelse derav
NO20011775L (no) Borefluidadditiver og fremgangsmåter derav
DK1454907T3 (da) Quninazolin og pyridopyrmidin-derivativer
DE60031119D1 (de) Richtbohrvorrichtung und -verfahren
IS5667A (is) 4-bensýlpíperidínalkýlsúlfoxíð-heteróhringir og not þeirra sem undirtegunda-valbundin nmda-þega-mótlyf
NO20006488D0 (no) Sammensetning og anvendelse
NO20010804D0 (no) Muskariniske agonister og antagonister
DE59608834D1 (de) Bohr- und Meisselgerät
NO20003449D0 (no) Sentraliseringsanordning
IS4947A (is) Tróvafloxasín mesýlat tafla
NO20004274D0 (no) Proteaseaktivert reseptor 4 og anvendelse derav
DE69921110D1 (de) Bohrflüssigkeiten und zusatzstoffen
NO20013237L (no) 3,3-biarylpiperidin og 2,2-biarylmorfolinderivater
DK1068238T3 (da) Integrinheterodimer og subunit deraf
NO963331D0 (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
DE69805154T2 (de) Programmierbares Gerät
DK1140952T3 (da) Phosphororganiske forbindelser og anvendelse heraf
ATE272118T1 (de) T-zell selektive interleukin-4 agoniste
NO20003268D0 (no) Hyperhydrert kitikolin, fremgangsmÕte og anvendelse
DE29810384U1 (de) Programmierbares Gerät
DK1127052T3 (da) Substituerede 2-phenylbenzimidazoler, fremstilling og anvendelse heraf
DK1133300T3 (da) Desmethylolanzapinsammensætninger og fremgangsmåder
DK1049777T3 (da) ACPL-DNA og -polypeptider